symptoms [8] . Currently, these investigations are used for research purposes, to understand the natural history and development of type 1 diabetes, and to identify individuals in whom prevention therapies can be tested.
However, cases like those of Peter Baldwin, and the significant proportion of children who present with DKA at diagnosis, make us question whether these screening tests should be rolled out to the general population. This is an emotive topic and one we should explore carefully. The current thinking on this subject suggests we should not be routinely screening for type 1 diabetes because there is no therapy currently proven to prevent or significantly delay the onset of this condition. This is supported by guidelines from respected authorities in this area [9] . However, this does not consider the benefits associated with early detection of type 1 diabetes, not least of which is prevention of death by DKA.
So, what are the benefits of screening for type 1 diabetes? A number of research studies have now outlined what these may be (Table 1) . These research studies have either screened the general population or been more focused and screened people deemed at risk because they have a family member with the disease. Screening has been undertaken through genetic and autoantibody tests followed by glucose tolerance tests for those deemed at risk. To date, screening studies have largely studied children and not explored adults (the age group in which almost 40% of type 1 diabetes presents). The benefit most consistently reported across these studies is avoidance of DKA. This is a significant benefit, with a reduction from a quarter of new type 1 diabetes being diagnosed in DKA down to 3%. Also, presumably because they are diagnosed at an earlier stage of disease, there is more residual beta cell function (as measured by C-peptide), lower insulin requirements and lower HbA 1c at the time of diagnosis [10] [11] [12] [13] [14] [15] . The paper by Lundgren and colleagues [4] adds to the evidence. They report from follow-up of the Diabetes Prediction in Skane (DiPiS) study, where almost 40,000 children in southern Sweden were screened for type 1 diabetes. Of these, 6000 were deemed to be at some degree of risk and offered Table 2 Screening for type 1 diabetes set against WHO criteria for screening [19] Criterion Satisfied
The condition sought should be an important health problem
Yes
Type 1 diabetes is an important health problem. Whilst early screening does not currently allow us to institute preventative therapy, it may prevent comorbidity associated with late presentation There should be an accepted treatment for patients with recognised disease
People at risk will be provided with education until they are formally diagnosed with diabetes, at which time they will be initiated on insulin. The psychological consequences of awareness of high risk of a chronic disease for which there is no cure is not known
The natural history of the condition, including development from latent to declared disease, should be adequately understood.
Not known
Natural history remains to be fully elucidated, different rates of progression remain to be understood. Age, ethnicity and environment appear to influence natural history and these effects remain to be elucidated [17, 18] . To provide some clarity, Table 2 presents the benefits of screening against the WHO guidelines for screening, originally proposed almost 50 years ago [19] . Here, the benefits relate to early detection, and not to prevention of the disease. There are a number of criteria that remain to be satisfied.
First, we do not know the psychological consequences of alerting a person to a condition for which there is no current cure. Granted, this time may usefully be spent in educating and preparing the person for managing type 1 diabetes. However, concurrent work on the psychological impact of informing patients of high risk of type 2 diabetes suggests that, even with a condition that can be significantly delayed, there can be a negative psychological impact. These include negative markers of mental health, reduced motivation and lack of engagement with behaviour change [20] .
Second, the natural history of type 1 diabetes is still not clearly understood, and the influence of age, ethnicity and environment remain to be elucidated. The environment may influence the rate of development, as evidenced by migration studies, where populations migrating from areas of low incidence to high appear to adopt the risk of the host population [21] . Whilst we previously believed that rates of beta cell loss were faster at a younger age, more recent work suggests that the rate may remain the same across the age spectrum [22] , despite islet histology changing with age of presentation [23] . Importantly, all major screening studies to date have focused on children.
Lastly, the cost benefit needs to be established for a formal screening programme. Since 2015 the Bavarian Fr1da study has been screening children aged 3-4 years for type 1 diabetes [24] . The aim is to screen 200,000 children, with each screening roughly costing 20 Euros per child. If DKA and hospitalisation is prevented in 200 children, this cost saving will in itself cover a third of the cost of the study. Furthermore, patients presenting with DKA tend to have an HbA 1c that is up to 1.4% higher than those who do not over the long term [3] . If the lower HbA 1c reported by Lundgren et al persists to reduce the incidence and economic impact of diabetic complications, combined with the saving on DKA cost, we may be a significant way to covering the economic cost of screening. Further work is required in this area.
Until some of the issues above are resolved (and there is significant work ongoing) the way forward is in public and healthcare education, and raising awareness. As a direct result of the efforts of Peter Baldwin's family, the Welsh government recently (October 2018) discussed ten recommendations around raising awareness of type 1 diabetes. These recommendations include adopting the Diabetes UK 4Ts campaign [25] , and a recommendation that all cases diagnosed in DKA are reviewed for shared learning [26] . These measures are critical if we are going to make a meaningful change to the devastation caused by death by DKA.
